Pharmaceutical Industry Information Portal

HomeTagsBiokhimik

All posts by tag

Biokhimik

New product from Promomed Group for protection, ensure the functioning and repair of the nervous system cells

Promomed Group has registered a new drug Brainmax®, reaffirming its commitment to the strategy of launching innovative, knowledge-based products. The technology developed by the...

Russian Ministry of Health included injectable Areplivir® in the guidelines for the treatment of COVID-19

The Ministry of Health of the Russian Federation has included the injectable form of the direct-acting antiviral drug Areplivir® (favipiravir) in the updated, fourteenth, version...

Biokhimik JSC of Promomed Group and Mordovia State University agreed on further cooperation

At the meeting of the management of Biokhimik JSC with Acting Rector of the Ogarev Mordovia State University Dmitry Glushko and the scientific community...

The first Russian injectable drug for treatment of COVID-19 is ap-proved

The first Russian direct-acting intravenous antiviral drug Areplivir® (favipiravir) received marketing authorization certificate and its supply to hospitals in all regions will start by...

Promomed Group and the Ministry of Economy, Trade and Entrepreneurship of the Republic of Mordovia signed an Agreement on the development of industrial tourism

On September 21, Biokhimik JSC (part of the Promomed Group) and the Ministry of Economy, Trade and Entrepreneurship of Mordovia signed an agreement on...

Areplivir developed by Promomed for the treatment of coronavirus infection received marketing authorization in Uzbekistan

Areplivir, included in the guidelines of the Ministry of Health of Russia for the treatment of COVID-19, received marketing authorization in Uzbekistan. On August 4,...
spot_img

Expert Articles

spot_img